Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
EVAX Stock Summary
Top 10 Correlated ETFs
EVAX
In the News
EVAX Stock Earnings: Evaxion Biotech Meets EPS for Q4 2023
Evaxion Biotech (NASDAQ: EVAX ) just reported results for the fourth quarter of 2023. Evaxion Biotech reported earnings per share of -$1.60.
Why Is Evaxion Biotech (EVAX) Stock Up 30% Today?
Evaxion Biotech (NASDAQ: EVAX ) stock is on the rise Wednesday after the company revealed a stake held by Merck (NYSE: MRK ). A filing with the Securities and Exchange Commission (SEC) notes that Merck now holds an 11.4% stake in Evaxion Biotech.
Evaxion (EVAX) Up on Partnership With Afrigen for Gonorrhea Jab
Evaxion's (EVAX) shares gain as it collaborates with Afrigen Biologics to develop prophylactic mRNA vaccine targeting gonorrhea, based on Evaxion's EDEN technology.
Evaxion Biotech A/S (EVAX) Q2 2023 Earnings Call Transcript
Evaxion Biotech A/S (EVAX) Q2 2023 Earnings Conference Call August 22, 2023 10:00 AM ET Company Participants Per Norlen - Chief Executive Officer Jesper Nyegaard Nissen - Chief Operating Officer and Interim Chief Financial Officer Conference Call Participants Thomas Flaten - Lake Street Ahu Demir - Ladenburg Thalmann Swayampakula Ramakanth - H.C. Wainwright Operator Good day, and thank you for standing by.
Evaxion presents promising results on EVX-B1, an AI-designed vaccine against Staphylococcus aureus
COPENHAGEN, Denmark, July 31, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the discovery and development of AI-powered immunotherapies, presents promising results of EVX-B1 at the Staphylococcal Diseases Gordon Research Conference in New Hampshire, USA.
Evaxion Biotech to announce clinical data for the personalized DNA cancer vaccine EVX-02 at the 2023 American Association for Cancer Research Annual Meeting (AACR)
COPENHAGEN, Denmark, March 14, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, today announced that the company will present clinical readout of the Phase 1/2a trial of EVX-02 at the upcoming 2023 American Association for Cancer Research Annual Meeting (2023 AACR), taking place from April 14th to April 19th in Orlando, Florida.
Evaxion to present a full clinical readout on two personalized cancer immunotherapies in Q2 2023
COPENHAGEN, Denmark, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, today announced that they expect to present data from their two clinical trials of personalized cancer immunotherapies (cancer vaccines) EVX-01 and EVX-02 in the second quarter of 2023.
Best Penny Stocks To Buy: 3 High Volume Stocks To Watch Today
High volume penny stocks to watch before next week. The post Best Penny Stocks To Buy: 3 High Volume Stocks To Watch Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Evaxion (EVAX) Enrolls First Patient in Phase IIb Melanoma Study
Evaxion (EVAX) enrolls the first patient in the phase IIb study evaluating its cancer therapy, EVX-01 in combination with Keytruda, for treating melanoma.
Good Penny Stocks to Add to Your Buy List? 3 to Watch
Which penny stocks are on your buy list right now? The post Good Penny Stocks to Add to Your Buy List?
EVAX Financial details
EVAX Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -2.88 | -5.83 | -9.27 | -12.58 | -9.8 | |
Operating cash flow per share | -1.04 | -3.66 | -7.68 | -11.25 | -10.9 | |
Free cash flow per share | -1.04 | -3.69 | -7.92 | -11.95 | -11.03 | |
Cash per share | 3.87 | 4.98 | 3.6 | 16.5 | 5.58 | |
Book value per share | -0.48 | 4.88 | 4.34 | -25.87 | -30.74 | |
Tangible book value per share | -0.48 | 4.88 | 4.28 | 16.59 | -30.74 | |
Share holders equity per share | -0.48 | 4.88 | 4.34 | -25.87 | -30.74 | |
Interest debt per share | 4.88 | 0.66 | 0.15 | 2.36 | 1.59 | |
Market cap | 189.87M | 189.87M | 160.2M | 86.16M | 41.96M | |
Enterprise value | 191.11M | 180.35M | 154.39M | 57.68M | 31.03M | |
P/E ratio | -34.3 | -16.96 | -10.67 | -3.51 | -1.81 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -95.37 | -27.02 | -12.88 | -3.93 | -1.63 | |
PFCF ratio | -95.03 | -26.79 | -12.49 | -3.7 | -1.61 | |
P/B Ratio | -203.95 | 20.28 | 22.76 | -1.71 | -0.58 | |
PTB ratio | -203.95 | 20.28 | 22.76 | -1.71 | -0.58 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -34.43 | -16.74 | -9.44 | -2.42 | -1.38 | |
EV to operating cash flow | -95.99 | -25.67 | -12.41 | -2.63 | -1.2 | |
EV to free cash flow | -95.65 | -25.45 | -12.03 | -2.48 | -1.19 | |
Earnings yield | -0.03 | -0.06 | -0.09 | -0.28 | -0.55 | |
Free cash flow yield | -0.01 | -0.04 | -0.08 | -0.27 | -0.62 | |
Debt to equity | -9.31 | 0 | 0 | -0.07 | -0.03 | |
Debt to assets | 1.02 | 0 | 0 | 0.09 | -0.04 | |
Net debt to EBITDA | -0.22 | 0.88 | 0.36 | 1.2 | 0.49 | |
Current ratio | 0.89 | 6.36 | 1.18 | 8.03 | 3.71 | |
Interest coverage | -8.06 | -8.89 | -74.3 | -28.23 | -16.75 | |
Income quality | 0.36 | 0.63 | 0.83 | 0.89 | 1.11 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | -0.01 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0.01 | 0 | 0 | |
Capex to operating cash flow | 0 | 0.01 | 0.03 | 0.06 | 0.01 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -0.09 | -0.75 | -3.74 | -3.95 | -0.51 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 5.61 | 25.29 | 30.11 | 85.59 | 82.33 | |
ROIC | -0.63 | -1.07 | -2.12 | 0.58 | 0.36 | |
Return on tangible assets | -0.65 | -1.01 | -1.27 | -0.61 | 0.39 | |
Graham Net | -1.1 | 4.45 | -0.74 | 12.78 | -0.5 | |
Working capital | -1.04M | 9.24M | 907K | 30.38M | 10.21M | |
Tangible asset value | -931K | 9.36M | 6.94M | 32.34M | -72.66M | |
Net current asset value | -1.06M | 9.24M | 907K | 26.98M | 251K | |
Invested capital | -9.31 | 0 | 0 | -0.07 | -0.03 | |
Average receivables | 1.45M | 851.5K | 1.36M | 1.85M | 1.35M | |
Average payables | 99K | 392.5K | 1.65M | 2.75M | 2.47M | |
Average inventory | -682.5K | -682.5K | -3.46M | -4.41M | -2.2M | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 2.91K | 9.14K | 3.03K | 1.33K | |
Days of inventory on hand | 0 | -0.03 | -23.86K | -2.02K | -1.59K | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0.13 | 0.04 | 0.12 | 0.27 | |
Inventory turnover | 0 | -13.5K | -0.02 | -0.18 | -0.23 | |
ROE | 5.95 | -1.2 | -2.13 | 0.49 | 0.32 | |
Capex per share | 0 | -0.03 | -0.24 | -0.7 | -0.12 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
Metric | History | 2022-11-14 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -2.41 | -2.85 | -2.42 | -2.1 | -2.05 | |
Operating cash flow per share | 0 | 7.26 | 0 | 0 | 0 | |
Free cash flow per share | 0 | 7.45 | 0 | 0 | 0 | |
Cash per share | 7.51 | 5.47 | 3.98 | 2.63 | 0.94 | |
Book value per share | -27.59 | -30.17 | -30.53 | 0.94 | -32.45 | |
Tangible book value per share | 5.68 | -30.17 | -30.53 | 0.94 | -32.45 | |
Share holders equity per share | -27.59 | -30.17 | -30.53 | 0.94 | -32.45 | |
Interest debt per share | 0.22 | 1.18 | 0.13 | 3.98 | 0.07 | |
Market cap | 55.06M | 42.75M | 29.14M | 35.45M | 23.04M | |
Enterprise value | 37.2M | 31.82M | 18.9M | 38.83M | 20.44M | |
P/E ratio | -2.4 | -1.56 | -1.17 | -1.56 | -1.01 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | 0 | 2.44 | 0 | 0 | 0 | |
PFCF ratio | 0 | 2.38 | 0 | 0 | 0 | |
P/B Ratio | -0.84 | -0.59 | -0.37 | 13.98 | -0.26 | |
PTB ratio | -0.84 | -0.59 | -0.37 | 13.98 | -0.26 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -6.92 | -4.93 | -3.09 | -6.9 | -3.59 | |
EV to operating cash flow | 0 | 1.82 | 0 | 0 | 0 | |
EV to free cash flow | 0 | 1.77 | 0 | 0 | 0 | |
Earnings yield | -0.1 | -0.16 | -0.21 | -0.16 | -0.25 | |
Free cash flow yield | 0 | 0.42 | 0 | 0 | 0 | |
Debt to equity | 0 | -0.03 | 0 | 4.14 | 0 | |
Debt to assets | 0 | -0.04 | 0 | 0.63 | 0 | |
Net debt to EBITDA | 3.32 | 1.69 | 1.68 | -0.6 | 0.46 | |
Current ratio | 0 | 3.71 | 0 | 2.81 | 0 | |
Interest coverage | -11.37 | -11.06 | -19.61 | -20.42 | -31.66 | |
Income quality | 0 | -2.55K | 0 | 0 | 0 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0.03 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 38.67 | 44.01 | 40.78 | 6.65 | 38.72 | |
ROIC | 0.09 | 0.09 | 0.08 | -0.36 | 0.06 | |
Return on tangible assets | -0.21 | 0.12 | 0.1 | -0.34 | 0.08 | |
Graham Net | 1.68 | -0.5 | -1.41 | -1.45 | -4.36 | |
Working capital | 17.85M | 10.21M | 10.24M | 7.32M | 2.61M | |
Tangible asset value | 13.55M | -72.66M | -78.72M | 2.54M | -89.76M | |
Net current asset value | 3.96M | 251K | -3.67M | -2.85M | -12.07M | |
Invested capital | 0 | -0.03 | 0 | 4.14 | 0 | |
Average receivables | 648K | 394.5K | 394.5K | 2.12M | 2.12M | |
Average payables | 1.22M | 1.04M | 1.04M | 842.5K | 842.5K | |
Average inventory | 0 | -1.25M | -1.25M | -2.12K | -2.12K | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | 0.09 | 0.09 | 0.08 | -2.24 | 0.06 | |
Capex per share | 0 | 0.18 | 0 | 0 | 0 |
EVAX Frequently Asked Questions
What is Evaxion Biotech A/S stock symbol ?
Evaxion Biotech A/S is a DK stock and trading under the symbol EVAX
What is Evaxion Biotech A/S stock quote today ?
Evaxion Biotech A/S stock price is $3 today.
Is Evaxion Biotech A/S stock public?
Yes, Evaxion Biotech A/S is a publicly traded company.